Tango Therapeutics, Inc. (TNGX)
TNGX Stock Price Chart
Explore Tango Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TNGX price movements and trends.
TNGX Company Profile
Discover essential business fundamentals and corporate details for Tango Therapeutics, Inc. (TNGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Sept 2020
Employees
155.00
Website
https://www.tangotx.comCEO
Malte Peters
Description
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
TNGX Financial Timeline
Browse a chronological timeline of Tango Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.31, while revenue estimate is $1.56m.
Earnings released on 13 May 2026
EPS came in at -$0.32 falling short of the estimated -$0.31 by -2.01%.
Earnings released on 5 Mar 2026
EPS came in at -$0.29 surpassing the estimated -$0.31 by +6.45%.
Earnings released on 4 Nov 2025
EPS came in at $0.13 surpassing the estimated $0.01 by +1.20k%, while revenue for the quarter reached $53.81m , beating expectations by +9.58k%.
Earnings released on 5 Aug 2025
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $3.18m , missing expectations by -50.34%.
Earnings released on 12 May 2025
EPS came in at -$0.36 falling short of the estimated -$0.34 by -5.88%, while revenue for the quarter reached $5.39m , missing expectations by -15.21%.
Earnings released on 27 Feb 2025
EPS came in at -$0.35 falling short of the estimated -$0.32 by -9.37%, while revenue for the quarter reached $4.12m , missing expectations by -48.64%.
Earnings released on 6 Nov 2024
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%, while revenue for the quarter reached $11.61m , beating expectations by +44.76%.
Earnings released on 7 Aug 2024
EPS came in at -$0.24 surpassing the estimated -$0.34 by +29.41%, while revenue for the quarter reached $19.88m , beating expectations by +167.86%.
Earnings released on 8 May 2024
EPS came in at -$0.35 falling short of the estimated -$0.31 by -12.90%, while revenue for the quarter reached $6.47m , missing expectations by -2.98%.
Earnings released on 18 Mar 2024
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%, while revenue for the quarter reached $5.43m , missing expectations by -34.12%.
Earnings released on 8 Nov 2023
EPS came in at -$0.23 surpassing the estimated -$0.34 by +32.35%, while revenue for the quarter reached $10.73m , beating expectations by +24.50%.
Earnings released on 7 Aug 2023
EPS came in at -$0.23 surpassing the estimated -$0.35 by +34.29%, while revenue for the quarter reached $14.60m , beating expectations by +92.59%.
Earnings released on 9 May 2023
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%, while revenue for the quarter reached $5.77m , missing expectations by -14.07%.
Earnings released on 27 Mar 2023
EPS came in at -$0.33 surpassing the estimated -$0.36 by +8.33%, while revenue for the quarter reached $6.41m , missing expectations by -0.45%.
Earnings released on 10 Nov 2022
EPS came in at -$0.33 falling short of the estimated -$0.32 by -3.13%, while revenue for the quarter reached $6.92m , beating expectations by +22.64%.
Earnings released on 10 Aug 2022
EPS came in at -$0.28 surpassing the estimated -$0.33 by +15.15%, while revenue for the quarter reached $5.77m , beating expectations by +1.97%.
Earnings released on 11 May 2022
EPS came in at -$0.29 falling short of the estimated -$0.28 by -3.57%, while revenue for the quarter reached $5.76m , missing expectations by -1.31%.
Earnings released on 28 Mar 2022
EPS came in at -$0.25 surpassing the estimated -$0.28 by +10.71%, while revenue for the quarter reached $5.72m , missing expectations by -13.06%.
Earnings released on 9 Nov 2021
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $6.79m , beating expectations by +8.33%.
Earnings released on 6 Aug 2021
EPS came in at -$0.05 , while revenue for the quarter reached $18.15m .
TNGX Stock Performance
Access detailed TNGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
